Amur Minerals Corporation (“Amur” or the “Company”), which has been reclassified as an AIM Rule 15 cash shell, announces an update regarding progress towards completing a Reverse Takeover (‘RTO’) pursuant to AIM Rule 14 (“RTO”).
The Company entered into a heads of terms agreement (“HOT”) to acquire a UK based candidate in the healthcare sector (the “Target”) on 25 January 2024. The Target is a UK-based pharmaceutical company which has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy.